OPKO Health Announces Application to Cease to be a Reporting Issuer in Canada
13 October 2016 - 9:30AM
Business Wire
OPKO Health, Inc. (NASDAQ: OPK), announces that in
connection with the acquisition of Transition Therapeutics Inc.,
Canadian securities regulation will deem OPKO to be a reporting
issuer in the provinces in which Transition was a reporting issuer,
unless OPKO applies for an order that those rules do not apply to
it on the basis that less than 2% of its shareholders reside in
Canada. As OPKO has a very small number of shareholders in Canada,
it will be applying for an order that it not be a reporting issuer
in any jurisdiction of Canada.
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks
to establish industry-leading positions in large, rapidly growing
markets. Our diagnostics business includes Bio-Reference
Laboratories, the nation's third-largest clinical laboratory with a
core genetic testing business and a 420-person sales force to drive
growth and leverage new products, including the 4Kscore prostate
cancer test and the Claros 1 in-office immunoassay platform. Our
pharmaceutical business features RAYALDEE, an FDA approved
treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency, and VARUBI™ for chemotherapy-induced nausea and
vomiting (oral formulation launched by partner Tesaro and IV
formulation PDUFA is January 2017). Our biologics business includes
hGH-CTP, a once-weekly human growth hormone injection (in Phase 3
and partnered with Pfizer), a long-acting Factor VIIa drug for
hemophilia (in Phase 2a) and a long acting oxyntomodulin for
diabetes and obesity (in Phase 1). We also have production and
distribution assets worldwide, multiple strategic investments and
an active business development strategy. More information is
available at www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and
other words of similar meaning, including statements regarding
OPKO’s application to cease to be a reporting issuer in Canada.
Many factors could cause our actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements. These factors include those described
in our Annual Reports on Form 10-K filed and to be filed with the
Securities and Exchange Commission and in our other filings with
the Securities and Exchange Commission. The forward-looking
statements contained in this press release speak only as of the
date the statements were made, and we do not undertake any
obligation to update forward-looking statements. We intend that all
forward-looking statements be subject to the safe-harbor provisions
of the PSLRA.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161012006376/en/
OPKO Health, Inc.Tara Mackay, 305-575-4100Investor
RelationsorMediaRooney & AssociatesTerry Rooney,
212-223-0689trooney@rooneyco.comorMarion Janic,
212-223-4017mjanic@rooneyco.comorInvestorsLHAAnne Marie
Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2024 to May 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From May 2023 to May 2024